Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia 4 Leukemia, Myeloid, Acute 3 Neutropenia 2 Leukemia, Myelomonocytic, Acute 2 Leukemia, Monocytic, Acute 2 Leukemia, Megakaryoblastic, Acute 2 Leukemia, Erythroblastic, Acute 2 Recurrence 1 Myelodysplastic Syndromes 1 Leukemia, Promyelocytic, Acute 1 Anemia, Refractory, with Excess of Blasts 1

Interventions

Dexamethasone 28 Rituximab 16 pomalidomide 14 Gemcitabine 12 Bortezomib 12 Lenalidomide 11 Cisplatin 11 Paclitaxel 10 Cyclophosphamide 8 Carboplatin 8 carfilzomib 7 daratumumab 6 selinexor 5 Drug Therapy 5 Doxorubicin 5 Cytarabine 5 ibrutinib 4 Vincristine 4 Temozolomide 4 Prednisone 4 Docetaxel 4 Calcium Dobesilate 4 Bevacizumab 4 Aspirin 4 tisagenlecleucel 3 Injections 3 Cetuximab 3 Bendamustine Hydrochloride 3 venetoclax 2 ofatumumab 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Recurrence × Amsacrine × Clear all

NCT03765541 2025-04-10

DEXAML-03

University Hospital, Toulouse

Phase 3 Terminated

Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon ⚡